Ketamine News and Research

RSS

Ketamine variant shows promise in treating social impairments

Well-being is important for everyone, especially when we feel lonely or isolated. Depression is a serious challenge for many people and finding an effective solution is key.

22 Feb 2024

Ketamine therapy for mental health a ‘wild West’ for doctors and patients

In late 2022, Sarah Gutilla's treatment-resistant depression had grown so severe, she was actively contemplating suicide.

31 Jan 2024

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

16 Jan 2024

Study offers new insights into ketamine's rewiring of the brain

Ketamine – an anesthetic also known for its illicit use as a recreational drug – has undergone a thorough reputational rehabilitation in recent years as the medical establishment has begun to recognize its wide-ranging therapeutic effects.

4 Dec 2023

Science tackles mental health: New tools against anxiety and depression in a stressed world

This review in the Proceedings of the National Academy of Sciences discusses the role of scientific tools in combating mental health disorders like anxiety, MDD, and PTSD, emphasizing the need for a deep scientific understanding and diverse treatment approaches in the face of a global surge in psychological stress. The study explores stress biology, treatment strategies, and the importance of personalized scientific approaches to effectively address the mental health crisis.

29 Nov 2023

UTS researcher tests new handheld device for rapidly and accurately identifying drug specimens

University of Technology Sydney (UTS) Centre for Forensic Science PhD candidate Harry Fursman is working on two fronts to prevent harm to people who use drugs: He is testing a new handheld device for rapidly and accurately identifying drug specimens and conducting ongoing chemical analysis of used syringes.

16 Nov 2023

LHPP gene identified as a potential target for treatment-resistant depression

Major depressive disorder (MDD) is a widespread mental health condition that for many is disabling. It has long been appreciated that MDD has genetic as well as environmental influences.

2 Nov 2023

Ketamine's long-lasting antidepressant effects unveiled in new study

Persistent blocking of NMDAR and burst-type firing by lateral habenula (LHb) neurons may offer a basis for the long-lasting antidepressant effects of ketamine.

22 Oct 2023

How ketamine treatment elicits long-lasting anti-depressive effects

Researchers discuss the mechanisms responsible for the sustained antidepressant effects of ketamine by examining ketamine-NMDAR interactions.

20 Oct 2023

Ketamine shows complex influence on social cognition in schizophrenia, study reveals

Researchers from the University of Bonn delve into the complex relationship between ketamine and social cognition deficits in schizophrenia, revealing both promising and cautionary insights.

12 Oct 2023

Intracellular journey: The penetration of antidepressants into cells, organelles, and membranes

Researchers in neuropsychopharmacology challenge conventional wisdom about antidepressants' actions, revealing significant intracellular activity that influences their effectiveness. Utilizing advanced technologies, the study prompts a reevaluation of drug targeting and mechanisms, opening new avenues for treating depression.

12 Oct 2023

Accelerating drug discovery with analytical R&D solutions

In this interview, Thermo Fisher Scientific discusses how to accelerate drug discovery through analytical R&D.

From Thermo Fisher Scientific – Materials & Structural Analysis 12 Oct 2023

Esketamine outperforms one of the standard drugs for treatment-resistant major depression

A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.

4 Oct 2023

Psychedelic drugs cause synchronized brain waves in rats, study finds

Researchers at Lund University have developed a technique for simultaneously measuring electrical signals from 128 areas of the brain in awake rats.

8 Aug 2023

Vanderbilt receives $7 million grant to study sedatives for critically ill patients

Vanderbilt University Medical Center has received a $7 million, five-year funding award from PCORI (Patient-Centered Outcomes Research Institute) to compare two sedatives used to place breathing tubes in the emergency department (ED) or intensive care unit (ICU).

18 Jul 2023

The DEA relaxed online prescribing rules during covid. Now it wants to rein them in.

Federal regulators want most patients to see a health care provider in person before receiving prescriptions for potentially addictive medicines through telehealth — something that hasn't been required in more than three years.

27 Jun 2023

World-renowned researcher receives top award for contributions to clinical psychopharmacology

Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System, has received the prestigious Donald Klein Lifetime Achievement Award from the American Society for Clinical Psychopharmacology (ASCP).

26 Jun 2023

Psychedelics reopen ‘critical periods’ for social reward learning, mice study shows

Neuroscientists have long searched for ways to reopen "critical periods" in the brain, when mammals are more sensitive to signals from their surroundings that can influence periods of brain development.

14 Jun 2023

$Study shows ketamine nasal spray as a safe and effective treatment for refractory migraine$

Study shows ketamine nasal spray as a safe and effective treatment for refractory migraine

Ketamine taken in the form of a nasal spray may prove a safe and effective treatment for refractory chronic migraine, suggests a single centre study, published in the open access journal Regional Anesthesia & Pain Medicine.

30 May 2023

Neuropathic pain study uncovers pathophysiological mechanism and promising therapeutic target

Neuropathic pain -; abnormal hypersensitivity to stimuli -; is associated with impaired quality of life and is often poorly managed. Estimates suggest that 3 percent to 17 percent of adults suffer from neuropathic pain, including a quarter of people with diabetes and a third of people with HIV.

5 May 2023